ID: ALA161650

Max Phase: Preclinical

Molecular Formula: C13H19ClN2

Molecular Weight: 238.76

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CN1CCN(CCc2ccccc2Cl)CC1

Standard InChI:  InChI=1S/C13H19ClN2/c1-15-8-10-16(11-9-15)7-6-12-4-2-3-5-13(12)14/h2-5H,6-11H2,1H3

Standard InChI Key:  JVGWNFZECLCIOG-UHFFFAOYSA-N

Associated Targets(Human)

Dopamine receptor 115 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 238.76Molecular Weight (Monoisotopic): 238.1237AlogP: 2.13#Rotatable Bonds: 3
Polar Surface Area: 6.48Molecular Species: NEUTRALHBA: 2HBD: 0
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 7.90CX LogP: 2.65CX LogD: 2.04
Aromatic Rings: 1Heavy Atoms: 16QED Weighted: 0.80Np Likeness Score: -1.67

References

1. Glennon RA, Salley JJ, Steinsland OS, Nelson S..  (1981)  Synthesis and evaluation of novel alkylpiperazines as potential dopamine antagonists.,  24  (6): [PMID:7252977] [10.1021/jm00138a007]

Source